McDonald’s Corporation (NYSE:MCD) is adapting its menu as a growing number of Americans on GLP-1 weight-loss drugs, such as Ozempic and Wegovy, alter portion sizes, snacking habits, and beverage choices.
During a Wednesday earnings call, CEO Chris Kempczinski said McDonald’s is testing menu items to appeal to customers taking GLP-1 medications.
“As adoption grows, we know that consumers’ behavior changes,” Kempczinski said.
He noted these customers tend to favor protein-rich meals.
Don’t Miss:
Vice President Jill McDonald highlighted high-protein options already on the menu, including Snack Wraps, Sausage Biscuit sandwiches, and McCrispy Strips.
“We’re also seeing changes around maybe less snacking, changes in some of the beverages that they drink, less sugary drinks,” Kempczinski added.
Jill McDonald confirmed the company has longer-term plans to serve this customer segment, but did not provide further details.
GLP-1 drug adoption in the U.S. has been rising steadily, with an estimated 10% of the population using these medications, which suppress appetite and reduce food intake.
Trending: It’s no wonder Jeff Bezos holds over $250 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started.
The trend is prompting companies across the food industry to adjust.
Conagra Brands and General Mills are offering smaller portion options labeled “GLP-1 friendly,” while Shake Shack introduced its “Good Fit Menu” featuring high-protein and lettuce-wrapped burger options.
Earlier this week, McDonald’s reported strong fourth-quarter 2025 results, beating analyst expectations with revenue of $6.83 billion and earnings per share of $3.05.
The company’s $5 meal deal helped boost U.S. same-store sales by 9%, appealing to budget-conscious consumers amid rising grocery costs.
See Also: From Moxy Hotels to $12B in Real Estate — The Firm Behind NYC’s Trendiest Properties Is Letting Individual Investors In.
Last year, McDonald’s stock climbed nearly 5% in a month, fueled by the $5 meal deal, which boosted U.S. same-store sales by 9% as consumers sought affordable options amid rising grocery costs.
